Total Payments
$121,261
2024 Payments
$418.32
Companies
11
Transactions
317
Medicare Patients
672
Medicare Billing
$68,820
Payment Breakdown by Category
Other$95,540 (78.8%)
Consulting$9,214 (7.6%)
Food & Beverage$8,542 (7.0%)
Travel$5,092 (4.2%)
Research$2,773 (2.3%)
Education$100.06 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $93,540 | 44 | 77.1% |
| Consulting Fee | $9,214 | 4 | 7.6% |
| Food and Beverage | $8,542 | 226 | 7.0% |
| Travel and Lodging | $5,092 | 23 | 4.2% |
| Unspecified | $2,773 | 16 | 2.3% |
| Honoraria | $2,000 | 1 | 1.6% |
| Education | $100.06 | 3 | 0.1% |
Payments by Type
General
$118,488
301 transactions
Research
$2,773
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $61,371 | 126 | $0 (2024) |
| Gilead Sciences, Inc. | $52,373 | 117 | $0 (2024) |
| Theratechnologies Inc. | $5,778 | 15 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $546.48 | 5 | $0 (2019) |
| Merck Sharp & Dohme LLC | $421.52 | 14 | $0 (2023) |
| Janssen Biotech, Inc. | $360.50 | 19 | $0 (2023) |
| EMD Serono, Inc. | $135.51 | 9 | $0 (2019) |
| Janssen Products, LP | $93.98 | 2 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $85.26 | 5 | $0 (2017) |
| PFIZER INC. | $77.97 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $418.32 | 12 | ViiV Healthcare Company ($228.75) |
| 2023 | $600.59 | 27 | ViiV Healthcare Company ($274.01) |
| 2022 | $5,683 | 22 | Gilead Sciences, Inc. ($2,913) |
| 2021 | $9,300 | 21 | ViiV Healthcare Company ($7,314) |
| 2020 | $14,748 | 15 | ViiV Healthcare Company ($11,121) |
| 2019 | $45,549 | 83 | ViiV Healthcare Company ($35,785) |
| 2018 | $28,634 | 82 | Gilead Sciences, Inc. ($19,063) |
| 2017 | $16,328 | 55 | Gilead Sciences Inc ($15,118) |
All Payment Transactions
317 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $31.37 | General |
| Category: HIV | ||||||
| 10/23/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $32.91 | General |
| Category: HIV | ||||||
| 08/23/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: HIV | ||||||
| 06/12/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: HIV | ||||||
| 06/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $144.87 | General |
| 05/16/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: HIV | ||||||
| 04/25/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $27.53 | General |
| Category: HIV | ||||||
| 03/28/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: HIV | ||||||
| 03/08/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $25.02 | General |
| Category: HIV | ||||||
| 02/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.88 | General |
| 02/08/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $26.34 | General |
| Category: HIV | ||||||
| 01/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.82 | General |
| 12/13/2023 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: VACCINES | ||||||
| 11/02/2023 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $27.54 | General |
| Category: HIV | ||||||
| 11/02/2023 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $27.54 | General |
| Category: HIV | ||||||
| 11/01/2023 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: VACCINES | ||||||
| 11/01/2023 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: HIV | ||||||
| 10/04/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $88.82 | General |
| 10/04/2023 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $23.96 | General |
| Category: HIV | ||||||
| 09/13/2023 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $19.75 | General |
| Category: HIV | ||||||
| 09/11/2023 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: HIV | ||||||
| 09/04/2023 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 08/24/2023 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: HIV | ||||||
| 08/01/2023 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $25.87 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 07/26/2023 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: HIV | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,598 | 8 |
| A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY | ViiV Healthcare Company | $1,175 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 90 | 230 | $71,096 | $16,860 |
| 2022 | 2 | 83 | 119 | $18,290 | $5,793 |
| 2021 | 6 | 253 | 492 | $79,644 | $20,011 |
| 2020 | 6 | 246 | 473 | $74,522 | $26,156 |
Total Patients
672
Total Services
1,314
Medicare Billing
$68,820
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 58 | 182 | $70,616 | $16,457 | 23.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 32 | 48 | $480.00 | $403.20 | 84.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 43 | 76 | $17,860 | $5,664 | 31.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 40 | 43 | $430.00 | $129.00 | 30.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 62 | 161 | $37,835 | $9,394 | 24.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 51 | 92 | $28,796 | $6,668 | 23.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 35 | 47 | $7,473 | $2,484 | 33.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 24 | 24 | $3,600 | $770.07 | 21.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 68 | 155 | $1,550 | $462.00 | 29.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 13 | 13 | $390.00 | $232.83 | 59.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 54 | 109 | $34,117 | $12,471 | 36.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 54 | 114 | $26,596 | $8,728 | 32.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 43 | 71 | $11,289 | $3,784 | 33.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 63 | 146 | $1,460 | $427.01 | 29.2% |
| 90674 | Vaccine for influenza for administration into muscle, 0.5 ml dosage | Office | 2020 | 14 | 14 | $490.00 | $409.22 | 83.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 18 | 19 | $570.00 | $337.67 | 59.2% |
About Dr. Clifford Kinder, MD
Dr. Clifford Kinder, MD is a Family Medicine healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1669476537.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Clifford Kinder, MD has received a total of $121,261 in payments from pharmaceutical and medical device companies, with $418.32 received in 2024. These payments were reported across 317 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($93,540).
As a Medicare-enrolled provider, Kinder has provided services to 672 Medicare beneficiaries, totaling 1,314 services with total Medicare billing of $68,820. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Miami, FL
- Active Since 06/09/2005
- Last Updated 05/06/2024
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1669476537
Products in Payments
- DOVATO (Drug) $43,642
- Biktarvy (Drug) $18,063
- Odefsey (Drug) $9,772
- JULUCA (Drug) $7,572
- Genvoya (Drug) $5,019
- CABENUVA (Biological) $4,597
- TROGARZO (Drug) $3,026
- TIVICAY (Drug) $865.45
- ISENTRESS (Drug) $328.69
- SYMTUZA (Drug) $307.98
- PIPELINE (Device) $300.80
- PREZCOBIX (Drug) $294.41
- EGRIFTA (Drug) $252.76
- APRETUDE (Biological) $188.71
- TRIUMEQ (Drug) $178.44
- SEROSTIM (Biological) $135.51
- Stribild (Drug) $121.25
- PIFELTRO (Drug) $92.83
- SUSTIVA (Drug) $85.26
- RUKOBIA (Drug) $74.69
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Miami
Keila Hoover, M.d, M.D
Family Medicine — Payments: $1.1M
Family Medicine $1.1M
Dr. Yamirka Duardo-Guerra, M.d, M.D
Family Medicine — Payments: $1.0M
Family Medicine $1.0M
Ramon Leon, Md, MD
Family Medicine — Payments: $179,798
Family Medicine $179,798
Mirel Sanchez, M.d, M.D
Family Medicine — Payments: $165,828
Family Medicine $165,828
Gilberto Seco, Md, MD
Family Medicine — Payments: $127,612
Family Medicine $127,612
Ana Elosegui, M.d, M.D
Family Medicine — Payments: $51,214
Family Medicine $51,214